Related Experiment Videos
High cost patients and the consortium approach
1Merton, Sutton & Wandsworth Health Authority, Mitcham, UK. susan.schonfield@mswha.sthames.nhs.uk
Pathophysiology of Haemostasis and Thrombosis
|September 6, 2002
Summary
The Pan-Thames Haemophilia Consortium improved regional planning for haemophilia services. High-cost therapies for a small patient group consumed a significant portion of the treatment budget.
Area of Science:
- Healthcare Management
- Public Health
- Hematology
Background:
- The establishment of the Pan-Thames Haemophilia Consortium aimed to centralize and optimize regional haemophilia service planning.
- An Expert Advisory Group was formed to address high-cost elective treatment programs within the consortium.
Purpose of the Study:
- To evaluate the initial year of the Pan-Thames Haemophilia Consortium's activities.
- To analyze the resource allocation for high-cost therapies within the consortium's budget.
Main Methods:
- An audit was conducted on the consortium's first year of operational data.
- Patient demographics and treatment expenditure were analyzed.
Main Results:
- Patients receiving high-cost therapy constituted 1.6% of the total patient population.
- These patients accounted for 16% of the overall treatment budget.
Conclusions:
- The consortium demonstrated focused commissioning expertise in managing specialized haemophilia services.
- The Pan-Thames model offers a framework for national commissioning strategies for haemophilia care.